This material safety data sheet is being provided to your company, for the purpose of providing current health and safety information to your management and employees who work with this product. please read the data provided and then provide it to those

FIRST PRIORITY, INC.
Date: September 27, 2004
PRODUCT NAME:
FUROSEMIDE SYRUP 1%
This Material Safety Data Sheet is being provided to your company, for the purpose of providing current health and safetyinformation to your management and employees who work with this product. Please read the data provided and then provideit to those people at your company who have the responsibility to insure compliance with both FEDERAL and STATE Right toKnow regulations, and to those employees that request information on this product.
Federal Regulations:
Parts 29 and 42 Code of Federal Regulations.
State of Illinois:
SECTION 1 - PRODUCT IDENTIFICATION
Manufacturer:
First Priority, Inc.
1585 Todd Farm Drive
Elgin, IL 60123

Telephone Number:
800-650-4899
Emergency Number:
Chemtrec
800-424-9300

Chemical Family:
Formula:
Hazard Classification:
HMIS Rating System:
SECTION 2 - HAZARDOUS COMPONENTS
Ingredient
The hazard communication standard requires that such mixtures be assumed to present the same health hazard as docomponents that constitute as least 1% of the mixture (0.1% for carcinogens) although OSHA has noted that the hazards ofindividual components may be altered by including them in a mixture. Some of the ingredients of this mixture are a tradesecret. NE = not established.
SECTION 3 - PHYSICAL DATA
Boiling Point:
Specific Gravity:
Vapor Pressure:
Percent Volatile:
Vapor Density:
Evaporation Rate:
Solubility in Water:
Appearance & Odor:
Light yellow colored liquid withalcoholic odor FIRST PRIORITY, INC.
Date: September 27, 2004
PRODUCT NAME:
FUROSEMIDE SYRUP 1%
SECTION 4 - FIRE & EXPLOSION DATA
Flash Point (Method):
Estimated Flammable Limits in Air:
Extinguishing Media:
Water, carbon dioxide or foam, Class A, BC or ABC fire extinguisher.
Special Fire Fighting Procedures:
Must wear MSHA/NIOSH approved self-contained breathing apparatus and protective clothing. Cool fire-exposed containers with water spray.
Unusual Fire & Explosion Hazards:
SECTION 5 - HEALTH HAZARD DATA
Effects Of Overexposure
Inhalation:
Ingestion:
Effect depends on the amount and rate of consumption.
Emergency First Aid Procedures:
Eye Contact:
Flush eyes with large amounts of water for at least 15 minutes.
Skin Contact:
Inhalation:
Remove to fresh air. Get immediate medical attention.
Ingestion:
If swallowed, immediately give 3-4 glasses of water. Get immediate medical atttention.
SECTION 6 - REACTIVITY DATA
Stability:
Conditions to avoid instability:
Incompatibility:
Hazardous Decomposition Byproducts:
Hazardous Polymerization:
SECTION 7 - SPILL OR LEAK PROCEDURES
Steps To Be Taken In Case Of Large Amount Of Material Is Released Or Spilled:
Sweep or scoop up and place in chemical waste containers. Wash area with soap and water. In normal use this product is
suitable for entry into an ordinary sanitary sewer system.
Waste Disposal Methods:
Dispose in accordance with all local, state and federal regulations. Contaminated absorbent may be deposited in a landfill in
accordance with local, state and federal regulations.
FIRST PRIORITY, INC.
Date: September 27, 2004
PRODUCT NAME:
FUROSEMIDE SYRUP 1%
SECTION 8 - SPECIAL PROTECTION
Respiratory Protection:
MSHA/NIOSH - approved breathing apparatus.
Ventilation:
Protective Gloves:
Eye Protection:
Use proper protection - safety glasses, as a minimum.
Other Protective Equipment:
SECTION 9 - SPECIAL PRECAUTIONS OR COMMENTS
Special precautions to be taken
in handling & storing:

Keep closures tight. Avoid exposure to excessive heat.
Other precautions:
Use adequate ventilation. Wash thoroughly after handling.
Initial Date:
Although the information and recommendations set forth herein (hereinafter “information”) are presented in good faith andbelieved to be correct as of the date hereof. First Priority, Inc. makes no representations as to the completeness or accuracythereof. Information is provided upon the condition that the persons receiving same will make their own determination as toits suitability for their purposes prior to use. In no event will First Priority, Inc. be responsible for damages of any naturewhatsoever resulting from use of or reliance upon said information presented herein. NO REPRESENTATIONS ORWARRANTIES, EITHER EXPRESSED OR IMPLIED, OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSEOR OF ANY OTHER NATURE ARE MADE HEREUNDER WITH RESPECT TO INFORMATION OR THE PRODUCT TOWHICH INFORMATION REFERS.

Source: http://www.prioritycare.com/docs/msds/msds_furosemidesyrup1.pdf

linus101.li.funpic.de

Genes and Immunity (2006) 00, 1–4& 2006 Nature Publishing Group All rights reserved 1466-4879/06 $30.00SHORT COMMUNICATIONThe interleukin-10 gene promoter polymorphismÀ1087AG does not correlate with clinical outcome in non-Hodgkin’s lymphomaD Kube1, T-D Hua1, M Klo¨ss2, B Kulle3,4, J Brockmo¨ller5, L Wojnowski5,6, M Lo¨ffler2, M Pfreundschuh7and L Tru¨mper11Department of Internal

Microsoft word - retosigmoidoscopia.doc

Retosigmoidoscopia CONSENTIMENTO INFORMADO Por este instrumento particular o(a) paciente________________________________________ou seu responsável,Sr.(a)_______________________________________, declara, para todos os fins legais, especialmente do disposto no artigo 39, VI, da Lei 8.078/90 que dá plena autorização ao (à) médico(a) assistente, Dr.(a)_________________________________

Copyright © 2010-2014 Medical Pdf Finder